Last reviewed 2026-05-31 · How we verify

Semagludtide

Novo Nordisk A/S · Phase 3 active Small molecule ✓ Verified May 2026

Semagludtide is a Small molecule drug developed by Novo Nordisk A/S. It is currently in Phase 3 development.

Semagludtide is being studied as a potential treatment for early Alzheimer's disease. It is a variant of semaglutide, a medication that is typically used to treat type 2 diabetes.

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Novo Nordisk A/S is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Semagludtide
Sponsor	Novo Nordisk A/S
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Semagludtide CI brief — competitive landscape report
Semagludtide updates RSS · CI watch RSS
Novo Nordisk A/S portfolio CI

Frequently asked questions about Semagludtide

What is Semagludtide?

Semagludtide is a Small molecule drug developed by Novo Nordisk A/S.

Who makes Semagludtide?

Semagludtide is developed by Novo Nordisk A/S (see full Novo Nordisk A/S pipeline at /company/novo-nordisk).

What development phase is Semagludtide in?

Semagludtide is in Phase 3.

Manufacturer: Novo Nordisk A/S — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing